GALECTIN THERAPEUTICS INC.

(GALT)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
1.320 USD   +0.76%
05/23Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conference and the 5th Global NASH Congress
AQ
05/17HC Wainwright Adjusts Price Target on Galectin Therapeutics to $11 From $14, Reiterates Buy Rating
MT
05/16Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Galectin Therapeutics to Present at the H.C. Wainwright BioConnect Conference

01/06/2022 | 08:02am EDT

NORCROSS, Ga., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be participating in the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. Mr. Joel Lewis, President and Chief Executive Officer, and Dr. Pol F. Boudes, Chief Medical Officer, will be presenting on behalf of the Company.

A webcast of this presentation will be available on the “Investor Relations” section under “Events and Presentations” of the Company’s website, https://investor.galectintherapeutics.com, at 7:00 a.m. ET on January 10, 2022. A replay will be accessible on Galectin’s website for 90 days following the event.

About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at www.galectintherapeutics.com.

Company Contact:

Jack Callicutt, Chief Financial Officer
(678) 620-3186
ir@galectintherapeutics.com

Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor GR-MD-02.


Primary Logo

Source: Galectin Therapeutics Inc.

2022 GlobeNewswire, Inc., source Press Releases

All news about GALECTIN THERAPEUTICS INC.
05/23Galectin Therapeutics to Present in Upcoming H.C. Wainwright Global Investment Conferen..
AQ
05/17HC Wainwright Adjusts Price Target on Galectin Therapeutics to $11 From $14, Reiterates..
MT
05/16Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 an..
AQ
05/16GALECTIN THERAPEUTICS INC Management's Discussion and Analysis of Financial Condition ..
AQ
05/16Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 3..
CI
05/16NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
04/14Galectin Therapeutics Says Study of Liver Disease Drug Candidate to Proceed Without Cha..
MT
04/14Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitor..
AQ
04/14Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitor..
CI
04/14GALECTIN THERAPEUTICS : Reports the Positive Outcome of the First Data and Safety Monitori..
PU
More news
Analyst Recommendations on GALECTIN THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -46,4 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,76x
Yield 2022 -
Capitalization 78,4 M 78,4 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 9
Free-Float 59,9%
Chart GALECTIN THERAPEUTICS INC.
Duration : Period :
Galectin Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALECTIN THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,32 $
Average target price 11,00 $
Spread / Average Target 733%
EPS Revisions
Managers and Directors
Joel Lewis President, Chief Executive Officer & Director
Jack W. Callicutt Chief Financial Officer & Secretary
Richard E. Uihlein Chairman
Pol F. Boudes Chief Medical Officer
Ezra R. lowe Executive Director-Clinical
Sector and Competitors
1st jan.Capi. (M$)
GALECTIN THERAPEUTICS INC.-36.23%78
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478